Risk groups in AMGs based on clinical/genomic risk factors. (A) Risk groups based on independent variables in the MV model including GEP-SFLC >25 mg/dL, serum M spike ≥3 g/dL, and GEP70 risk score >−0.26. (B) Risk groups based on independent clinical variables in the MV model: serum M-protein ≥3 g/dL, bone marrow PCs ≥20%, and age ≥65 years. (C) Time-to-progression to CMM requiring therapy in cohorts based on GEP70 score and disease subtype (AMM or MGUS). (D) Time-to-progression to CMM requiring therapy in AMM patients based on risk factors 0, 1, or 2+ (risk factors: SFLC >25 mg/dL, serum M spike ≥ 3g/dL, and GEP70 risk score >−0.26). N, number; RF, risk factors.